SCHEMBL29368994

SCHEMBL29368994

Nc1ccc(N=Nc2ccc3cc(S(=O)(=O)O)c(N=Nc4ccc(N=Nc5ccc(N)cc5N)c(S(=O)(=O)O)c4)c(O)c3c2)c(N)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CD40 P25942 1/20 0.52
▸ CD40LG P29965 1/20 0.52
▸ ENPP2 Q13822 7/20 0.49
▸ CYP1A2 P05177 1/20 0.46
▸ PHLPP2 Q6ZVD8 1/20 0.46
▸ SENP2 Q9HC62 5/20 0.45
▸ SUMO2 P61956 3/20 0.45
▸ SUMO1 P63165 3/20 0.45
▸ SENP7 Q9BQF6 3/20 0.45
▸ ATIC P31939 1/20 0.45
▸ SENP1 Q9P0U3 4/20 0.45
▸ SENP3 Q9H4L4 3/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CA2 P00918 1/20 0.43
▸ CA3 P07451 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14164004 0.87 CD40 (0.50) CD40CD40LGENPP2CYP1A2PHLPP2
SCHEMBL10600651 0.87 PHLPP2 (0.51) CD40CD40LGENPP2CYP1A2PHLPP2
SCHEMBL14351150 0.84 PHLPP2 (0.55) CD40CD40LGENPP2PHLPP2SENP2
SCHEMBL11876652 0.84 ENPP2 (0.60) CD40CD40LGENPP2CYP1A2PHLPP2
SCHEMBL9400781 0.83 SENP2 (0.58) CD40CD40LGENPP2CYP1A2PHLPP2
SCHEMBL14163986 0.83 KDM4E (0.50) CD40CD40LGENPP2PHLPP2SENP2
SCHEMBL13840886 0.83 CYP1A2 (0.63) CD40CD40LGENPP2CYP1A2PHLPP2
SCHEMBL14466096 0.83 CD40 (0.72) CD40CD40LGENPP2PHLPP2SENP2
SCHEMBL12387775 0.82 ENPP2 (0.55) ENPP2CYP1A2PHLPP2SENP2SUMO2
SCHEMBL19628859 0.82 ENPP2 (0.55) ENPP2CYP1A2PHLPP2SENP2SUMO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694899-A1 METHODS AND MATERIALS FOR TREATING CANCER Mayo Foundation for Medical Education and Research (US) 2026-02-18 — — EP claimed
WO-2025072717-A1 TREATING CANCER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-04-03 — — WO claimed
WO-2025054471-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-03-13 — — WO claimed
WO-2024215881-A1 METHODS AND MATERIALS FOR TREATING CANCER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-10-17 — — WO claimed
CN-116694506-B Lactobacillus plantarum HYY-DB36 and application thereof 佛山科学技术学院 2024-09-10 — — CN claimed
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-25 — — US claimed
CN-116694506-A Lactobacillus plantarum HYY-DB36 and application thereof 佛山科学技术学院 2023-09-05 — — CN claimed
CN-111401480-B Novel mammary gland MRI automatic auxiliary diagnosis method based on fusion attention mechanism 上海市同济医院 2023-07-25 — — CN claimed
CN-115136858-A Rice-plantago efficient crop rotation ecological planting technology and application 江西省中医药研究院 2022-10-04 — — CN claimed
CN-217305256-U Novel DB head cable test tool 珠海市泓立泰科技有限公司 2022-08-26 — — CN claimed
CN-114565574-A Navel orange damage detection method 陈定虎 2022-05-31 — — CN claimed
US-20260134731-A1 INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND RECORDING MEDIUM NEC CORPORATION (JP) 2026-05-14 — — US disclosed
US-20260112222-A1 INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND RECORDING MEDIUM NEC CORPORATION (JP) 2026-04-23 — — US disclosed
EP-4694899-A1 METHODS AND MATERIALS FOR TREATING CANCER Mayo Foundation for Medical Education and Research (US) 2026-02-18 — — EP disclosed
US-12518325-B2 Electric power system planning operation device, method, and system HITACHI, LTD. (JP) 2026-01-06 — — US disclosed
JP-2022041196-A RENTAL MEETING ROOM USE MANAGEMENT DEVICE, METHOD AND PROGRAM 東京瓦斯株式会社 2022-03-11 — — JP disclosed
US-20220062260-A1 COMBINATION THERAPY FOR TREATMENT OF LKB1 DEFICIENT CANCERS NEW YORK UNIVERSITY 2022-03-03 — — US disclosed
US-11256278-B2 Power system stabilization device and power system stabilization method HITACHI, LTD. (JP) 2022-02-22 — — US disclosed
CN-110572767-B Information processing apparatus, wireless communication terminal, and information processing method 丰田自动车株式会社 2022-02-08 — — CN disclosed
CN-113986153-A Information processing system, information processing apparatus, information processing method, information processing transmission apparatus, information processing transmission method, and recording medium 富士胶片商业创新有限公司 2022-01-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260112222-A1 INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND RECORDING MEDIUM NCS1, USE1, SAMM50 CD40 1667/4885CD40LG 3598/4885ENPP2 3915/4885
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME NES, NFE2L2, NUCB2 CD40 4648/4885CD40LG 3728/4885ENPP2 3657/4885
US-20260134731-A1 INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND RECORDING MEDIUM SAMM50, CACNA2D4, CACNA2D1 CD40 1303/4885CD40LG 2957/4885ENPP2 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback